Trial Profile

Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Apr 2026 According to Grace Therapeutics media release, the results from the trial will be presented at the upcoming 2026 American Academy of Neurology annual meeting, 2026.
14 Apr 2026 Results presented in the Grace Therapeutics media release.
19 Mar 2026 According to a Grace Therapeutics media release, the Society of Critical Care Medicines Critical Care Congress, to be held March 22-24, 2026 in Chicago, IL and at the American Association of Neuroscience Nurses annual meeting, to be held March 21-24, in Dallas, TX.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com